MTOR and osteosarcoma: Similarly, NVP-BEZ235, a dual pan-PI3K-mTOR inhibitor, exhibits anti-proliferative effects in a panel of osteosarcomas and showed synergistic activity with chemotherapeutic agents and with other small signaling inhibitors [8].